Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.86 SEK | -3.18% |
|
-3.49% | +3.76% |
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.76% | 1.09B | B | ||
-4.98% | 184B | C+ | ||
-3.78% | 103B | C | ||
-5.00% | 67.59B | A | ||
+15.15% | 46.93B | B- | ||
-9.69% | 43.87B | B- | ||
+8.28% | 41.2B | B+ | ||
+17.08% | 30.47B | B | ||
+13.59% | 24.16B | A- | ||
-8.01% | 23.57B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ARJO B Stock
- Ratings Arjo AB